Development of Provenge for Prostate Carcinoma Therapy

Provenge, as an autologous cell immunotherapy agent, was originally used to stimulate the immune cells and immunologic factors to destroy prostate cancinoma cells. For patients with hormone resistant metastatic ovarian cancer, when there are no clinical symptoms, compared to the placebo arm, the drug arm can effectively extend the median survival period of four point one months. During the three years of treatment, more than 50% of patients in the immunotherapy arm survived, and more than 50% of patients in the control group survived (31.7% vs 21.7%). Provenge, targeted to release prostate acid phosphatase, utilizes the patient's immune cells to detect and eliminate tumor cells. At the moment, there are not useful therapeutic strategies for asymptomatic patients without docetaxel and other chemical drugs treatment. The direct strategy to increase the effectiveness of Provenge is to promote more effective clinical benefits. Although the preclinical analysis and clinical efficacy of Provenge have been summarized, the clinical efficacy of enhancing efficacy needs to be reconsidered